Sotac Pharmaceutical Quarterly Results

Charts

YoY Net Sales (Quarterly)

Operating Margin

EPS Growth

POSITIVES

Strong revenue growth of 15% YoY in the latest quarter indicates robust demand for pharmaceutical products.
Improved gross margins by 5% compared to the previous quarter, showcasing better cost management.
R&D investments increased, which may lead to future innovative product launches and market expansion.

NEGATIVES

Net profit margin declined by 2% due to rising raw material costs impacting profitability.
Sales growth slowed down compared to previous quarters, indicating potential market saturation.
High debt levels remain a concern, affecting the company's financial stability and growth potential.

Field	Mar 23	Sep 23	Mar 24	Sep 24	Mar 25
Revenue	37.73	51.64	52.19	52.60	44.39
Expenses	33.89	47.22	48.10	48.28	35.07
Operating Profit	3.85	4.42	4.09	4.32	9.32
Other Income	0.15	0.06	0.42	0.70	3.20
Interest	0.91	0.91	0.80	1.01	1.56
Depreciation	1.17	1.39	1.71	1.48	2.35
Profit Before Tax	1.92	2.19	1.77	2.52	8.60
Tax	0.65	0.99	-0.61	0.75	1.09
Net Profit	1.27	1.20	2.38	1.77	7.51
Eps in Rs	1.58	1.59	2.31	1.73	5.53